ECSP077246A - Formulaciones Estabilizadoras - Google Patents
Formulaciones EstabilizadorasInfo
- Publication number
- ECSP077246A ECSP077246A EC2007007246A ECSP077246A ECSP077246A EC SP077246 A ECSP077246 A EC SP077246A EC 2007007246 A EC2007007246 A EC 2007007246A EC SP077246 A ECSP077246 A EC SP077246A EC SP077246 A ECSP077246 A EC SP077246A
- Authority
- EC
- Ecuador
- Prior art keywords
- protein
- storing
- methods
- relatively low
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se describen formulaciones que son adecuadas para el almacenamiento de proteínas, tal como anticuerpos, sobre un rango relativamente amplio de concentraciones de proteína, pH, y tipos de tampón. También se describen métodos de almacenamiento de una proteína y métodos para identificar una formulación adecuada para el almacenamiento de una proteína específica. En general, una formulación que contiene poco o nada de surfactante, desde nada a concentraciones relativamente bajas de sal, y que requiere una concentración de tampón relativamente baja.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077246A true ECSP077246A (es) | 2007-05-30 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007246A ECSP077246A (es) | 2004-08-13 | 2007-02-13 | Formulaciones Estabilizadoras |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (es) |
| EP (1) | EP1784219B1 (es) |
| JP (1) | JP4948407B2 (es) |
| KR (1) | KR20070092197A (es) |
| CN (1) | CN101022831A (es) |
| AR (1) | AR051009A1 (es) |
| AU (1) | AU2005272603A1 (es) |
| BR (1) | BRPI0514340A (es) |
| CA (1) | CA2575870A1 (es) |
| CR (1) | CR8904A (es) |
| EC (1) | ECSP077246A (es) |
| ES (1) | ES2637854T3 (es) |
| IL (1) | IL181265A0 (es) |
| MX (1) | MX2007001599A (es) |
| NO (1) | NO20070930L (es) |
| RU (1) | RU2007109062A (es) |
| TW (1) | TW200621282A (es) |
| WO (1) | WO2006020935A2 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| US8945564B2 (en) * | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| MX2008013535A (es) * | 2006-04-21 | 2008-10-29 | Amgen Inc | Agentes amortiguadores para formulaciones biofarmaceuticas. |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| MX2009010361A (es) | 2007-03-29 | 2009-10-16 | Abbott Lab | Anticuerpos il-12 anti-humanos cristalinos. |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| NZ622583A (en) * | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
| AU2009319856A1 (en) * | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
| WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| PT2473528E (pt) | 2009-09-03 | 2015-03-04 | Ablynx NV | Formulações estáveis de polipéptidos e seus usos |
| EP2726090B1 (en) | 2011-07-01 | 2020-01-01 | Biogen MA Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions |
| AU2012345768B2 (en) | 2011-11-30 | 2016-05-12 | Kindeva Drug Delivery L.P. | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| RU2644214C2 (ru) * | 2012-03-26 | 2018-02-08 | Санофи | СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| WO2015065954A1 (en) | 2013-11-04 | 2015-05-07 | Pfizer, Inc. | Anti-efna4 antibody-drug conjugates |
| EP4035664A3 (en) | 2014-03-28 | 2022-11-30 | Duke University | Treating cancer using selective estrogen receptor modulators |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| JP6629831B2 (ja) * | 2014-07-21 | 2020-01-15 | アンチェインド ラブス | Δｇ値の濃度依存性に基づくタンパク質凝集の定量 |
| MX393599B (es) | 2015-04-29 | 2025-03-19 | Radius Pharmaceuticals Inc | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| HUE066064T2 (hu) | 2016-08-18 | 2024-07-28 | Regeneron Pharma | Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével |
| EP3528787B1 (en) | 2016-10-21 | 2026-01-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| DK3565542T3 (da) | 2017-01-05 | 2024-07-01 | Radius Pharmaceuticals Inc | Polymorphic forms of rad1901-2hcl |
| KR102792490B1 (ko) | 2018-07-04 | 2025-04-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| MX2021009569A (es) | 2019-02-12 | 2021-09-08 | Radius Pharmaceuticals Inc | Procesos y compuestos. |
| AU2021262609A1 (en) * | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| TW202245823A (zh) * | 2021-01-14 | 2022-12-01 | 南韓商韓兀生物製藥股份有限公司 | 無穩定劑或實質上無穩定劑之含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）的穩定眼用組成物 |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0041768B1 (en) | 1980-04-24 | 1987-11-11 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6852703B1 (en) | 1997-06-04 | 2005-02-08 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
| DK0999853T3 (da) * | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| WO1999037329A1 (en) | 1998-01-22 | 1999-07-29 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| WO2001047554A1 (fr) * | 1999-12-28 | 2001-07-05 | Chugai Seiyaku Kabushiki Kaisha | Compositions d'anticorps stables et preparations pour injection |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| JP2005532258A (ja) * | 2002-01-03 | 2005-10-27 | スミスクライン・ビーチャム・コーポレイション | 免疫コンジュゲートの調製方法 |
| DK1507556T3 (en) * | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
| CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| BRPI0413575A (pt) | 2003-08-14 | 2006-10-17 | Wyeth Corp | anticorpos anti-idiotìpicos anti-lewis y e seus usos |
| CN101035564A (zh) * | 2004-09-10 | 2007-09-12 | 惠氏公司 | 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物 |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es not_active Expired - Lifetime
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja not_active Expired - Fee Related
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Withdrawn
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en not_active Expired - Lifetime
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en not_active Ceased
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20070930L (no) | 2007-05-14 |
| JP4948407B2 (ja) | 2012-06-06 |
| BRPI0514340A (pt) | 2008-06-10 |
| IL181265A0 (en) | 2007-07-04 |
| ES2637854T3 (es) | 2017-10-17 |
| JP2008515775A (ja) | 2008-05-15 |
| EP1784219B1 (en) | 2017-05-17 |
| MX2007001599A (es) | 2007-04-10 |
| CA2575870A1 (en) | 2006-02-23 |
| WO2006020935A2 (en) | 2006-02-23 |
| WO2006020935A3 (en) | 2007-03-08 |
| CN101022831A (zh) | 2007-08-22 |
| EP1784219A2 (en) | 2007-05-16 |
| AU2005272603A1 (en) | 2006-02-23 |
| TW200621282A (en) | 2006-07-01 |
| EP1784219A4 (en) | 2010-02-17 |
| RU2007109062A (ru) | 2008-09-20 |
| US20060115472A1 (en) | 2006-06-01 |
| AR051009A1 (es) | 2006-12-13 |
| KR20070092197A (ko) | 2007-09-12 |
| CR8904A (es) | 2007-08-28 |
| US8871201B2 (en) | 2014-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077246A (es) | Formulaciones Estabilizadoras | |
| CY1121461T1 (el) | Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες | |
| TR201905081T4 (tr) | Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler. | |
| AR059964A1 (es) | Metodos para reducir la aglomeracion de proteina | |
| MX2010008416A (es) | Composiciones antimicrobianas y metodos de uso de las mismas. | |
| CO6382079A2 (es) | Composiciones insecticidas estables a base de sulfoximina | |
| CR9620A (es) | Composicion agricola | |
| AR047949A1 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial | |
| MX2009006594A (es) | Formulaciones de ph regulado y estables que contienen polipeptidos. | |
| PE20120342A1 (es) | Formulacion de anticuerpo | |
| ES2513716T3 (es) | Enzimas lecitina-colesteros acitransferasa modificadas | |
| ECSP088962A (es) | Nuevos herbicidas | |
| JP2017222654A5 (es) | ||
| PE20070796A1 (es) | Metodo de produccion proteica utilizando compuestos anti-senescencia | |
| AR055708A1 (es) | Composicion de acaros, uso de la misma, metodo para criar un acaro predatorio phytoseiid, sistema de crianza para criar dicho acaro predatorio phytoseiid y metodos para el control biologico de pestes en un cultivo | |
| PE20091783A1 (es) | Anticuerpos anti-factor d humanizados | |
| BR102014025328B8 (pt) | Composição herbicida aquosa estável, e método para controle de vegetação indesejável | |
| SV2006002513A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp | |
| ATE508190T1 (de) | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien | |
| UA100851C2 (ru) | Средство для борьбы с паразитами на животных | |
| ES2570599T3 (es) | Composición suave para desinfección cutánea | |
| MY157394A (en) | Ultra-high loading glyphosate concentrate | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
| AR118536A1 (es) | Composiciones y métodos para estabilizar formulaciones que contienen proteína |